<DOC>
	<DOCNO>NCT00723229</DOCNO>
	<brief_summary>We propose study episode rate , duration , quantity HSV-2 genital shed patient take standard , FDA approve , CDC recommend dos acyclovir ( 400 mg PO BID ) HSV-2 suppression compare take medication well define effect acyclovir short burst rapidly clear HSV-2 shed . This study randomize , open label , cross-over trial . We hypothesize short burst HSV-2 reactivation suppress acyclovir .</brief_summary>
	<brief_title>A Randomized Trial Evaluated Suppressive Effect Acyclovir Rapidly Cleared HSV-2 Reactivation</brief_title>
	<detailed_description>We propose study episode rate , duration , quantity HSV-2 genital shed patient take standard , FDA approve , CDC recommend dos acyclovir ( 400 mg PO BID ) HSV-2 suppression compare take medication well define effect acyclovir short burst rapidly clear HSV-2 shed . This study randomize , open label , cross-over trial . We propose perform study two study population . Cohort 1 comprise 25 HSV-2 seropositive , HIV seronegative adult , Cohort 2 comprise 25 HSV-2 seropositive , HIV seropositive adult CD4 count &gt; 250 cells/mm3 . As suppression HSV-2 use acyclovir currently study large , multi-center , international clinical trial HIV prevention strategy , result broad implication public health around world .</detailed_description>
	<mesh_term>Herpes Genitalis</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>COHORT 1 : HIV seronegative 1 . Older 18 year ; 2 . HSV2 seropositive Western Blot ; 3. receive drug know antiHSV2 activity study duration ; 4. woman child bear potential sexually active men must use medically accept method contraception judge investigator ; 5. woman childbearing potential must negative pregnancy test ( urine ) screen visit ; 6. general good health , without serious medical condition specifically normal renal hepatic function , determine patient 's medical history ; 7. planning remain resident area study center duration study participation ; 8 . HIV seronegative COHORT 2 : HIV seropositive 1 . Older than18 year ; 2 . HSV2 seropositive Western Blot ; 3. receive drug know antiHSV2 activity study duration ; 4. woman child bear potential sexually active men must use medically accept method contraception judge investigator ; 5. woman childbearing potential must negative pregnancy test ( urine ) screen visit ; 6. general good health , without serious medical condition specifically normal renal hepatic function , determine patient 's medical history ; 7. planning remain resident area study center duration study participation ; 8 . HIV seropositive 9 . CD4 count 250 cell/mm3 10 . Not take antiretroviral therapy For cohort : 1. hypersensitivity acyclovir valacyclovir ; 2. pregnant woman ; 3 . Taking immunosuppressive therapy , chronic oral steroid immune modulatory drug . For cohort 2 : 1 . CD4 count &lt; 250 cell/mm3 2 . Taking antiretroviral therapy time study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>